


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-7: (Canceled)

8. (Currently Amended) A method of treatment for Type II diabetes and its complications and associated conditions comprising administering a compound selected from formula (1) (Gibberellins)



Formula (1)

wherein

R¹ is H or a group –O-R²⁰, where R²⁰ is H or a glycosylic ether group (glycoside ether), or R¹ together with R² forms a bond (C₁– C₂ double bond);

R² is H or a group –O-R²¹, where R²¹ is H, a glycosylic ether group (glycoside ether), or R² together with R¹ or R³ forms a bond (C₁-C₂ or C₂-C₃ double bond, respectively);

R³ is H, =O, or –O-R²², where R²² is H or a glycosylic ether group (glycoside ether), or R³ together with R² forms a bond (C₂-C₃ double bond);

R⁴ together with R²⁸ forms a bond (lactone);

R⁵ is H or ~~a glycosylic ester (glycoside ester) group, or unsubstituted or substituted C_{1~20} alkyl esters, allyl esters, active esters;~~

R⁶ is H or OH or together with R⁷ forms a bond (C₁₁-C₁₂ double bond);

R⁷ is H or -OR²⁶, where R²⁶ is H or ~~a glycosylic ether group (glycoside ether) or R⁷ together with R⁶ forms a bond (C₁₁-C₁₂ double bond);~~

R⁸ is H[,] or hydroxyl[,] or ~~OR²⁷, where R²⁷ is a glycosylic ether group (glycoside ether);~~

R⁹ is H or OH;

R¹⁰ is -OR²⁸, where R²⁸ together with R⁴ forms a bond (lactone) ;

R¹¹ is absent;

R¹² is CH₃;

R¹³ is methylene;

R¹⁴ is H;

R¹⁵ is H;


and its pharmaceutically acceptable lactones, esters, active esters, salts and organic bases, in combination with other compatible therapeutic agents selected from the group

consisting of analgesics, anti-hypertensive agents, sedatives, hypnotics, lipid-lowering agents, and anti-infective agents or combinations thereof, to a patient in need thereof.

9. (Previously presented) A method according to claim 11, wherein the Gibberellins are Gibberellin A₃.

10. (Previously presented) A method according to claim 11, wherein the Gibberellins are a mixture of Gibberellin A₃ and Gibberellin A₄ and/or Gibberellin A₇.

11. (Currently Amended) A method of treatment for Type I or Type II diabetes and its complications and associated conditions comprising administering compounds selected from formula (1) (Gibberellins)



wherein

R¹ is H or a group -O-R²⁰, where R²⁰ is H or a glycosylic ether group (glycoside ether), or R¹ together with R² forms a bond (C₁-C₂ double bond);

R² is H or a group -O-R²¹, where R²¹ is H, a glycosylic ether group (glycoside ether), or R² together with R¹ or R³ forms a bond (C₁-C₂ or C₂-C₃ double bond, respectively);

R³ is H, =O, or –O-R²², where R²² is H or a glycosylic ether group (glycoside ether), or R³ together with R² forms a bond (C₂-C₃ double bond);

R⁴ together with R²⁸ forms a bond (lactone);

R⁵ is H or a glycosylic ester (glycoside ester) group, or unsubstituted or substituted C_{1~20} alkyl esters, allyl esters, active esters;

R⁶ is H or OH or together with R⁷ forms a bond (C₁₁-C₁₂ double bond);

R⁷ is H or –OR²⁶, where R²⁶ is H or a glycosylic ether group (glycoside ether) or R⁷ together with R⁶ forms a bond (C₁₁-C₁₂ double bond);

R⁸ is H[,] or hydroxyl[,] or –OR²⁷, where R²⁷ is a glycosylic ether group (glycoside ether);

R⁹ is H or OH;

R¹⁰ is –OR²⁸, where R²⁸ together with R⁴ forms a bond (lactone) ;

R¹¹ is absent;

R¹² is CH₃;


R¹³ is methylene;

R¹⁴ is H;

R¹⁵ is H;

and their pharmaceutically acceptable lactones, esters, active esters, salts and organic bases, in combination with substances selected from the group consisting of insulin, its fragment derivatives, IGFs, and growth factors, or combinations thereof, to a patient in need thereof.

12. (Currently Amended) A method of treatment for Type I or Type II diabetes and its complications and associated conditions comprising administering compounds selected from formula (1) (Gibberellins)



wherein

R¹ is H or a group —O-R²⁰, where R²⁰ is H or a glycosylic ether group (glycoside ether), or R¹ together with R² forms a bond (C₁—C₂ double bond);

R² is H or a group —O-R²¹, where R²¹ is H, a glycosylic ether group (glycoside ether), or R² together with R¹ or R³ forms a bond (C₁-C₂ or C₂-C₃ double bond, respectively);

R³ is H, =O, or —O-R²², where R²² is H or a glycosylic ether group (glycoside ether), or R³ together with R² forms a bond (C₂-C₃ double bond);

R⁴ together with R²⁸ forms a bond (lactone);

R⁵ is H or a glycosylic ester (glycoside ester) group, or unsubstituted or substituted C₁₋₂₀ alkyl esters, allyl esters, active esters;

R⁶ is H or OH or together with R⁷ forms a bond (C₁₁-C₁₂ double bond);

R⁷ is H or -OR²⁶, where R²⁶ is H or a glycosylic ether group (glycoside ether) or R⁷ together with R⁶ forms a bond (C₁₁-C₁₂ double bond);

R⁸ is H[[,]] or hydroxyl[[,]] or -OR²⁷, where R²⁷ is a glycosylic ether group (glycoside ether);

R⁹ is H or OH;

R¹⁰ is -OR²⁸, where R²⁸ together with R⁴ forms a bond (lactone) ;

R¹¹ is absent;

R¹² is CH₃;

R¹³ is methylene;

R¹⁴ is H;

R¹⁵ is H;

and its pharmaceutically acceptable lactones, esters, active esters, salts and organic bases, in combination with substances selected from the group consisting of insulin, its fragment derivatives, IGFs, and growth factors, or combinations thereof, along with other compatible therapeutic agents selected from the group consisting of analgesics,

anti-hypertensive agents, sedatives, hypnotics, lipid-lowering agents, and anti-infective agents or combinations thereof, to a patient in need thereof.

13. (Previously presented) The method according to claim 11, for the treatment of Type 1 diabetes and its associated conditions.

14. (Previously presented) The method according to claim 11, for the treatment of Type 2 diabetes and its associated conditions.

15. (Previously presented) The method according to claim 14, for the treatment of insulin resistant diabetes.

16. (Currently Amended) The method according to claim 4 11, wherein the diabetic related complications and associated conditions are chosen from obesity, micro and macro vascular diseases, nephropathy, neuropathy and eye diseases.

Claims 17-38: (Canceled)

39. (Previously presented) The method of claim 11, wherein the complications and associated conditions of diabetes are one or more of: obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, and diabetic ulcerations.

40. (Previously presented) The method of claim 11, wherein the pharmaceutically acceptable salts are selected from alkali metal salts, alkaline earth metal salts, metal, and salts of ammonium or salts of organic bases.

41. (Previously presented) The method of claim 40, wherein the organic bases are lidocaine, or NR¹⁶ R¹⁷ R¹⁸ R¹⁹, where R¹⁶, R¹⁷, R¹⁸, R¹⁹, which may be the same or not the same, are hydrogen, or substituted or unsubstituted C₁₋₂₀ alkyl, alkanol, or aryl groups.